Vol. 19/No. 8 | OncologyLive

FTase Inhibition Holds Promise for RAS Targeting and Beyond

May 16, 2018

Although mutant RAS has proved to be a challenging therapeutic target, recent success with tipifarnib, a biologically active drug known as a farnesyltransferase inhibitor, brings promise for treating solid tumors and hematological malignancies.

New Strategies Emerge for Urgent Care in Oncology

May 15, 2018

The incidence of emergency department visits and subsequent hospitalizations among patients with cancer is relatively common. Cancer-specific urgent care, pathways for symptom management, and more education for patients and healthcare providers are among the approaches that are being implemented to address patients’ needs and manage costs.

Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer

May 15, 2018

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Right-to-Try Laws: Let's Move Beyond the Rhetoric

May 15, 2018

Maurie Markman, MD, shares his thoughts on the right-to-try bill, which would allow terminally ill patients to receive investigational drugs that have been studied in phase I trials without applying through the FDA’s expanded access program.